Azenta, Inc. Releases Financial Results for Second Quarter of Fiscal 2025 Ending March 31

Azenta's Financial Report for Q2 FY2025

Azenta, Inc. (Nasdaq: AZTA), a global provider of life sciences solutions, has reported its financial performance for the second quarter ended March 31, 2025. The results reveal a steady revenue growth despite the business landscape's challenges.

Summary of Financial Highlights

The company experienced a revenue of $143 million from continuing operations, indicating a 5% increase year-over-year. Organic revenue growth, which excludes foreign exchange impacts, was an impressive 6%. Two of Azenta's primary operations, Sample Management Solutions and Multiomics, contributed to this growth, achieving revenues of $80 million (an 8% increase year-over-year) and $64 million (a 2% increase year-over-year), respectively.

Focused on Progress

Azenta's performance exhibited its resilience in a fluctuating macroeconomic environment. As its President and CEO, John Marotta, stated, "We delivered another quarter of strong performance... Our dedication to customers, coupled with our differentiated products and services, continues to steer us towards long-term growth."

Despite a reported diluted EPS continuing operations of 40, a significant reduction from the previous year, the company's adjusted EPS of $0.05 shows its potential for profitability. The company attributed the operating losses primarily to R&D expenses and restructuring initiatives.

Operational Strategies and Cost Management

Operating expenses were meticulously managed, with an overall decline of 3% year-over-year. Lower research and development costs, alongside a careful approach to sales and administrative expenses, contributed to this decline. Azenta's gross margin improved to 45.9%, a reflection of its effective sales mix and operational efficiencies.

The total operating loss narrowed to $16 million, showcasing a comparative improvement against previous periods. Non-GAAP operating metrics reinforced the company's positioning and strategies, revealing an adjusted EBITDA of $14 million and a margin of 10% for continuing operations.

Cash Position and Future Outlook

As of March 31, 2025, Azenta's liquidity stood at $540 million, underscoring its healthy cash position and setting the stage for continued investment in its growth strategies. The company remains confident, reiterating its revenue guidance for fiscal 2025, which anticipates organic growth within a range of 3% to 5% relative to fiscal 2024.

Concluding Remarks

As Azenta navigates the difficulties presented by the current business environment, its focus remains on reinforcing its operational efficiencies and enhancing economic performance. With a well-established balance sheet and strategic growth plans, Azenta is poised for a solid path forward. The company's management encourages stakeholders to remain engaged with the ongoing developments, which they believe will lead to significant advancements in the life sciences sector.

Future Communications

The company plans to host a conference call on May 7, 2025, at 8:30 AM ET, to discuss these results further and provide insights on future strategies and market conditions. Interested parties can attend via Azenta's Investor Relations website to get first-hand details on their plans and projections.

For more information, please visit Azenta's website.